Published Paper Details:

Surgical and chronic wounds often pose significant clinical challenges due to the risks of infection and delayed healing. While mupirocin is a widely used topical antibiotic effective against Gram-positive bacteria, particularly Staphylococcus aureus, it lacks direct wound-healing properties. Sucralfate, traditionally employed for gastrointestinal ulcers, has demonstrated potent wound-healing capabilities through mechanisms such as angiogenesis, epithelialisation, and the stimulation of local growth factors. Recent studies have investigated the synergistic benefits of combining sucralfate with mupirocin to enhance healing outcomes in various wound types. Clinical evidence has shown that this combination significantly improves healing rates in chronic ulcers compared to mupirocin alone (41.3% vs. 18.18%, P = 0.022). Although some findings remain context-dependent, in diabetic foot ulcers, the dual-action therapy offers notable advantages: infection control via mupirocin and tissue regeneration via sucralfate. In the context of surgical wounds, sucralfate provides a protective barrier over incisions, reducing mechanical irritation and enhancing local growth factor activity. These properties contribute to improved epithelial regeneration and reduced healing time in post-operative settings. Mechanistically, this combination addresses two critical aspects of wound care, making it a promising approach for both acute and chronic wound management. Further large-scale and multicenter trials are warranted to validate its efficacy across broader patient populations.